|
Dr. Paul Keck Receives
the Gerald L. Klerman Senior Investigator Award from the Depression and
Bipolar Support Alliance
The Gerald L. Klerman Senior Investigator Award is given annually to a
senior investigator with lifetime contributions to understanding the
causes, diagnosis, and treatment of depressive and bipolar illnesses.
Dr. Keck is a pioneer in the development of new therapies to treat
bipolar disorder. He was instrumental in the development of a wide range
of anticonvulsant compounds.
Dr. Keck also conducted the largest randomized double-blind placebo
controlled study to date. Through this study he concluded that EPA, an
omega-3 fatty acid, was a promising treatment for bipolar disorder in
young adults. Dr. Keck is recognized around the world for his work in
both researching treatments for bipolar disorder and for his
understanding of its related symptoms and functions.
The Gerald L. Klerman Awards are the highest recognition given by DBSA.
The awards are named after Gerald L. Klerman, M.D., one of DBSA's
earliest supporters. A major figure in psychiatry, he lead the first
multi-site study to understand the diagnosis, clinical course, and
genetics of major depression. This 30-year longitudinal study is still
on-going and has provided the baseline information on the course of
depression.
Dr. Klerman conducted the first clinical trial showing the efficacy of
medication and psychotherapy in the prevention of recurrent depression.
For this trial he developed interpersonal psychotherapy, an evidence-
based treatment widely used today and modified for the adjunct treatment
of medicated patients with bipolar disorder.
For more information
on the Klerman Award winners, or information on depression and bipolar
disorder, please contact DBSA by calling 800/826-3632 or by visiting
www.DBSAlliance.org. | 
